Skip to main content
main-content

Hematologic cancers: Immunotherapy

Journal articles and book chapters

06-08-2018 | Guidelines | Article

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Mahadeo KM et al. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0075-2.

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

16-02-2018 | Immunotherapy | Article

Using immunotherapy to boost the abscopal effect

Ngwa W et al. Nat Rev Cancer 2018; 18: 313–322. doi:10.1038/nrc.2018.6

15-11-2017 | Leukemia | Article

Agents in Development for Childhood Acute Lymphoblastic Leukemia

Maloney KW & Gore L. Pediatr Drugs 2017. doi:10.1007/s40272-017-0268-7

31-08-2017 | Lymphoma | Article

Chimeric antigen receptor T-cell therapies for lymphoma

​​​​​​​Nat Rev Clin Oncol 2017. doi:10.1038/nrclinonc.2017.128

05-08-2017 | Lymphoma | Article

Targeting Immune System Alterations in Hodgkin Lymphoma

This review by Grover et al. discusses novel immunotherapeutic approaches to treat Hodgkin lymphoma, specifically programmed cell death-1 (PD-1) inhibitors and cellular immunotherapy.

Grover NS, Savoldo B. Curr Hematol Malig Rep 2017. doi:10.1007/s11899-017-0398-6

31-07-2017 | Leukemia | Article

Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy

Fesnak and colleagues explore the issues surrounding the development of technologies for engineered T cell immunotherapy of B cell leukemia and lymphoma.

Fesnak AD et al. Curr Hematol Malig Rep 2017; 12: 335-343. doi:10.1007/s11899-017-0395-9

25-07-2017 | Acute myeloid leukemia | Article

Recent developments in immunotherapy of acute myeloid leukemia

This review surveys the current most prominent concepts in the immunotherapy of acute myeloid leukemia as well as the considerable progress made over the past few years.

Lichtenegger FS et al. J Hematol Oncol 2017; 10: 142. doi:10.1186/s13045-017-0505-0

22-07-2017 | Lymphoma | Article

An update on the use of immunotherapy in the treatment of lymphoma

This review by Marron et al. covers promising data on advances in antibody-based therapies, immunomodulators and checkpoint-blocking therapies in the treatment of lymphomas.

Marron TU, Kalac M, Brody J. Curr Hematol Malig Rep 2017. doi:10.1007/s11899-017-0396-8

23-02-2017 | Multiple myeloma | Article

CARs in the lead against multiple myeloma

Clinical success of CD19-directed chimeric antigen receptor T-cell therapy in leukemia has led to increased interest in applying this to other hematological malignancies – the authors thus summarize clinical trial results using this therapy in multiple myeloma.

Ormhøj M et al. Curr Hematol Malig Rep 2017; 12: 119–125. doi:10.1007/s11899-017-0373-2

02-02-2017 | Treatment | Article

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

Results from this preclinical study indicate that blocking programmed death-1 (PD-1)/PD-1 ligand interactions in conjunction with other immune checkpoint proteins provides synergistic anti-tumor efficacy following lymphodepletive doses of whole body irradiation.

Jing W et al. J Immunotherapy Cancer 2015; 3: 2. doi:10.1186/s40425-014-0043-z

29-12-2016 | Lymphoma | Article

The landscape of new drugs in lymphoma

In this review, Younes et al describe the most promising agents in clinical development for the treatment of lymphoma and provide expert opinion on new strategies that may streamline drug development.

Nat Rev Clin Oncol 2017; 14: 335–346. doi:10.1038/nrclinonc.2016.205

03-11-2015 | Hematologic cancers | Article

Novel immunotherapies in lymphoid malignancies

An evaluation of the development of three distinct immunotherapy platforms for lymphoma treatment: chimeric antigen receptor T-cell therapy, bispecific T-cell engagers, and immune checkpoint inhibitors.

Nat Rev Clin Oncol 2016; 13: 25–40. doi:10.1038/nrclinonc.2015.187

28-10-2014 | Pediatric leukemia | Article

Immune-based therapies for childhood cancer

Mackall et al. review immunotherapies with established efficacy in pediatric cancers as well as immunotherapies under study. The authors also highlight the emerging science driving this rapidly moving field.

Mackall CL et al. Nat Rev Clin Oncol 2014; 11: 693–703. doi:10.1038/nrclinonc.2014.177

Image Credits